OTCMIZOZF
Market cap6mUSD
Jan 10, Last price
0.12USD
1D
-4.00%
1Q
87.15%
IPO
-52.00%
Name
Izotropic Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.88%
Rev. gr., 5y
%
Revenues
0k
Net income
-2m
L-72.42%
CFO
-594k
L-81.83%
Earnings
Mar 31, 2025
Profile
Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 1,625 | 5,168 | 6,270 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (1,625) | (5,168) | (6,270) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 294 | 20 | ||||||
Tax Rate | ||||||||
NOPAT | (1,625) | (5,462) | (6,290) | |||||
Net income | (1,561) -72.42% | (5,661) -14.93% | (6,655) 33.73% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 710 | 1,815 | 531 | |||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 2,041 | 2,083 | 2,028 | |||||
Long-term debt | 72 | 145 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 2,074 | 2,062 | 172 | |||||
| Cash flow | ||||||||
Cash from operating activities | (594) | (3,266) | (4,764) | |||||
CAPEX | (36) | (24) | ||||||
Cash from investing activities | (36) | (24) | ||||||
Cash from financing activities | 468 | 1,612 | 2,581 | |||||
FCF | (806) | (4,495) | (5,856) | |||||
| Balance | ||||||||
Cash | 39 | 166 | 1,857 | |||||
Long term investments | ||||||||
Excess cash | 39 | 166 | 1,857 | |||||
Stockholders' equity | (5,010) | (4,739) | (375) | |||||
Invested Capital | 3,220 | 3,805 | 2,028 | |||||
ROIC | ||||||||
ROCE | 90.81% | 552.78% | ||||||
| EV | ||||||||
Common stock shares outstanding | 53,861 | 50,091 | 43,101 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (1,566) | (5,137) | (6,263) | |||||
EV/EBITDA | ||||||||
Interest | 253 | 294 | 20 | |||||
Interest/NOPBT | ||||||||